ISPE's 40th Annual Meeting - GIPAM will be presenting results of a cancer registry data analysis on RW treatment and OS in aNSCLC patients

Due to our CR efforts, GIPAM’s carbon emissions (scope 1-3) were as low as 2.5 tons in 2023. Thanks to our commitment to spend 0.5% of our fee turnover for climate projects, we could not only compensate for our carbon emissions but overcompensate them by 4,000%.

JCA on oncology and ATMPs is less than 12 months away, and the expected timetable for the publication of the implementing acts of the EU HTA Regulation has only recently been updated.

Therefore, we are pleased to invite you to our upcoming 2nd session (How to plan and support the JCA dossier development?) next Wednesday (March 6th, 16:00 – 17:30 pm).

GIPAM will host a webinar series for market access professionals in the pharmaceutical industry on the challenges of the upcoming joint clinical assessment (JCA) process.

WEBINAR 1 - February 28, 2024: How to do early strategic evidence generation planning under the new common EU-HTA regulation?

WEBINAR 2 - March 6, 2024: How to plan and support the JCA dossier development?

Secukinumab fails the health technology assessment (HTA) in Germany in the context of the indication extension for hidradenitis suppurativa (HS). This example shows the high importance of comparative evidence in Germany. In addition, such evidence will even play a more important role in the upcoming Joint Clinical Assessments (JCA) on EU level from 2025 onwards.

Feel free to contact us for more detailed insights!

ISPOR Europe 2023 is coming. The GIPAM leadership team is looking forward to a sensational conference and many fruitful discussions.

Thomas Wilke is going to present current options and innovative approaches around Pay-for-Performance reimbursement solutions at the upcoming FoGes symposium in Munich on the 24th of October.

GIPAM has entered into a strategic partnership with Core Clinical Sciences.

CCS’s expertise in simulation and modeling for clinical trials as well as advanced analytics solutions will naturally complement our expertise in Strategic Market Access Consulting and Real-World Evidence studies at GIPAM.

That it is possible to obtain superior G-BA assessment grades was recently shown by Esketamin in therapy-resistant major moderate to severe depression.

Feel free to contact us for more detailed insights!

GIPAM tracks regularly published G-BA decisions on potential implications for future HTA/market access strategies. Ibrutinib, in combination with Venetoclax, was a recent assessment (July 2023) that has important strategic implication..

Feel free to contact us for more detailed insights!

We are excited to announce that our new European consultancy, GIPAM, became operational on the 1st of September, and along with it, we are more than happy to release our website.

Together with the ZKN institute at the University of Dresden and the German sickness fund AOK PLUS, a data set that links claims data since 2010 for more than 500 patients with all their relevant clinical MS data (medical record data) has been generated.